期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/ijms23073507
关键词
SARS-CoV-2; main protease (Mrpo); HIV-1; resistance; drug resistance; PAXLOVID; PF-07321332; nirmatrelvir; protease inhibitor
资金
- National Research, Development and Innovation Fund of Hungary [TKP2021-EGA-20]
- [TKP2021-EGA]
COVID-19 is a devastating pandemic caused by SARS-CoV-2. The lack of effective antiviral drugs has led to global health crises. Pfizer's newly approved nirmatrelvir has shown promise as an inhibitor of the viral main protease, offering hope for both therapeutic and prophylactic use against the infection. However, the high mutation rates of RNA viruses highlight the importance of considering lessons learned from previous pandemics to avoid the emergence of resistance mutations in long-term use of novel inhibitors.
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 2 (SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of potent novel antivirals had led to global health crises; however, emergence and approval of potent inhibitors of the viral main protease (Mpro), such as Pfizer's newly approved nirmatrelvir, offers hope not only in the therapeutic front but also in the context of prophylaxis against the infection. By their nature, RNA viruses including human immunodeficiency virus (HIV) have inherently high mutation rates, and lessons learnt from previous and currently ongoing pandemics have taught us that these viruses can easily escape selection pressure through mutation of vital target amino acid residues in monotherapeutic settings. In this paper, we review nirmatrelvir and its binding to SARS-CoV-2 Mpro and draw a comparison to inhibitors of HIV protease that were rendered obsolete by emergence of resistance mutations, emphasizing potential pitfalls in the design of inhibitors that may be of important relevance to the long-term use of novel inhibitors against SARS-CoV-2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据